Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2020

16.05.2020 | Research Article

Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer

verfasst von: G. Ingrosso, C. Mariucci, M. V. Tenti, V. Bini, E. Alì, S. Saldi, I. Palumbo, R. Bellavita, C. Aristei

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metastasis-directed therapy (MDT) is an investigational treatment option in patients with oligorecurrent prostate cancer (PCa). The aim of this retrospective study is to report oncologic outcome and toxicity of elective nodal radiotherapy (ENRT) in PCa patients affected by pelvic nodal oligorecurrence.

Methods

41 consecutive patients were treated with salvage radiotherapy. At biochemical recurrence after primary treatment, oligorecurrent disease was detected by positron emission tomography (PET) in 94% of the patients. Image-guided intensity modulated radiation therapy (IMRT) was delivered using tomotherapy. 83% of the patients received androgen deprivation therapy (ADT) in combination with ENRT. Survival analysis was performed with Kaplan–Meier method, log-rank test was used to analyze associations between survival end-points and clinical parameters. Multivariate analysis was performed using Cox proportional hazards regression models. Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Results

The median at follow-up was 33.6 months. At 3 years, overall survival (OS), cancer-specific survival (CSS), and biochemical progression-free survival (b-PFS) were 89%, 92%, and 53%, respectively. At univariate analysis, all survival end-points were correlated with the number of positive pelvic lymph nodes at oligorecurrence (≤ 3 vs > 3). Biochemical-PFS was correlated with PSA (p = 0.034) and PSA doubling time (p = 0.004) at oligorecurrence. At multivariate analysis, no independent variable was statistically significant. No patient experienced grade ≥ 2 late toxicity after radiotherapy.

Conclusions

The number of metastatic lymph nodes and PSA doubling time seems to be important prognostic factors in the pelvic oligorecurrent setting. Salvage radiotherapy combined with short-course ADT might be a valid treatment strategy.
Literatur
1.
Zurück zum Zitat Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol. 2004;172:910–4.CrossRef Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol. 2004;172:910–4.CrossRef
2.
Zurück zum Zitat Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51:1175–84.CrossRef Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51:1175–84.CrossRef
4.
Zurück zum Zitat Lancia A, Zilli T, Achard V, et al. Oligometastatic prostate cancer: the game is afoot. Cancer Treat Rev. 2019;73:84–90.CrossRef Lancia A, Zilli T, Achard V, et al. Oligometastatic prostate cancer: the game is afoot. Cancer Treat Rev. 2019;73:84–90.CrossRef
5.
Zurück zum Zitat De Bruycker A, De Bleser E, Decaestecker K, et al. Nodal oligorecurrent prostate cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates. Eur Urol. 2019;75:826–33.CrossRef De Bruycker A, De Bleser E, Decaestecker K, et al. Nodal oligorecurrent prostate cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates. Eur Urol. 2019;75:826–33.CrossRef
6.
Zurück zum Zitat Mazzola R, Cuccia F, Figlia V, et al. New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming? Transl Androl Urol. 2019;8:S538–S541541.CrossRef Mazzola R, Cuccia F, Figlia V, et al. New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming? Transl Androl Urol. 2019;8:S538–S541541.CrossRef
7.
Zurück zum Zitat Alongi F, Fersino S, Giaj Levra N, et al. Impact of 18F-choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med. 2015;40:e496–500.CrossRef Alongi F, Fersino S, Giaj Levra N, et al. Impact of 18F-choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med. 2015;40:e496–500.CrossRef
8.
Zurück zum Zitat De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76:732–9.CrossRef De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76:732–9.CrossRef
9.
Zurück zum Zitat Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852–63.PubMed Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852–63.PubMed
10.
Zurück zum Zitat Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.CrossRef Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.CrossRef
11.
Zurück zum Zitat Phillips R, Lim SJ, Shi WY, et al. Primary outcomes of a phase II randomized trial of observation versus stereotactic ablative radiation for OLigometastatic Prostate CancEr (ORIOLE). Int J Radiat Oncol Biol Phys. 2019;105:681.CrossRef Phillips R, Lim SJ, Shi WY, et al. Primary outcomes of a phase II randomized trial of observation versus stereotactic ablative radiation for OLigometastatic Prostate CancEr (ORIOLE). Int J Radiat Oncol Biol Phys. 2019;105:681.CrossRef
12.
Zurück zum Zitat Ploussard G, Almeras C, Briganti A, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983–8.CrossRef Ploussard G, Almeras C, Briganti A, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983–8.CrossRef
13.
Zurück zum Zitat Fodor A, Berardi G, Fiorino C, et al. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU Int. 2017;119:406–13.CrossRef Fodor A, Berardi G, Fiorino C, et al. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU Int. 2017;119:406–13.CrossRef
14.
Zurück zum Zitat Nicosia L, Franzese C, Mazzola R, et al. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol. 2020;196:213–21.CrossRef Nicosia L, Franzese C, Mazzola R, et al. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol. 2020;196:213–21.CrossRef
15.
Zurück zum Zitat Supiot S, Rio E, Pacteau V, et al. OLIGOPELVIS-GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer. 2015;15:646.CrossRef Supiot S, Rio E, Pacteau V, et al. OLIGOPELVIS-GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer. 2015;15:646.CrossRef
16.
Zurück zum Zitat Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE. 2011;6:e28650.CrossRef Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE. 2011;6:e28650.CrossRef
17.
Zurück zum Zitat Fodor A, Lancia A, Ceci F, et al. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: nodal oligorecurrent prostate cancer. World J Urol. 2019;37:2607–13.CrossRef Fodor A, Lancia A, Ceci F, et al. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: nodal oligorecurrent prostate cancer. World J Urol. 2019;37:2607–13.CrossRef
18.
Zurück zum Zitat Tran S, Jorcano S, Falco T, et al. Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41:960–2.CrossRef Tran S, Jorcano S, Falco T, et al. Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41:960–2.CrossRef
19.
Zurück zum Zitat Ingrosso G, Trippa F, Maranzano E, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017;35:45–9.CrossRef Ingrosso G, Trippa F, Maranzano E, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017;35:45–9.CrossRef
20.
Zurück zum Zitat Ponti E, Lancia A, Ost P, et al. Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus. 2017;3:538–44.PubMed Ponti E, Lancia A, Ost P, et al. Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus. 2017;3:538–44.PubMed
21.
Zurück zum Zitat Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000.
22.
Zurück zum Zitat McCarthy M, Francis R, Tang C, et al. A multicenter prospective clinical trial of [68]Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 2019;104:801–8.PubMed McCarthy M, Francis R, Tang C, et al. A multicenter prospective clinical trial of [68]Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 2019;104:801–8.PubMed
24.
Zurück zum Zitat Kjölhede H, Ahlgren G, Almquist H, et al. 18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol. 2014;32:965–70.PubMed Kjölhede H, Ahlgren G, Almquist H, et al. 18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol. 2014;32:965–70.PubMed
25.
Zurück zum Zitat Evans JD, Jethwa KR, Ost P, et al. Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol. 2018;8:28–39.PubMed Evans JD, Jethwa KR, Ost P, et al. Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol. 2018;8:28–39.PubMed
26.
Zurück zum Zitat Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90.PubMed Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90.PubMed
27.
Zurück zum Zitat Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37.PubMed Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37.PubMed
28.
Zurück zum Zitat Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52:1622–8.PubMed Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52:1622–8.PubMed
29.
Zurück zum Zitat Panje C, Zilli T, Pra AD, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019;14:177.PubMedPubMedCentral Panje C, Zilli T, Pra AD, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019;14:177.PubMedPubMedCentral
30.
Zurück zum Zitat Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.CrossRef Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.CrossRef
31.
Zurück zum Zitat Lépinoy A, Silva YE, Martin E, et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:40–8.CrossRef Lépinoy A, Silva YE, Martin E, et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:40–8.CrossRef
32.
Zurück zum Zitat Vaugier L, Palpacuer C, Rio E, et al. Early toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07). Int J Radiat Oncol Biol Phys. 2019;103:1061–7.CrossRef Vaugier L, Palpacuer C, Rio E, et al. Early toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07). Int J Radiat Oncol Biol Phys. 2019;103:1061–7.CrossRef
Metadaten
Titel
Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer
verfasst von
G. Ingrosso
C. Mariucci
M. V. Tenti
V. Bini
E. Alì
S. Saldi
I. Palumbo
R. Bellavita
C. Aristei
Publikationsdatum
16.05.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02364-0

Weitere Artikel der Ausgabe 12/2020

Clinical and Translational Oncology 12/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.